Rocket Pharmaceuticals (RCKT) had its price target raised by Bank of America Corporation from $8.00 to $9.00. They now have a "buy" rating on the stock.
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI [Yahoo! Finance]
Rocket Pharmaceuticals (RCKT) Is Down 8.9% After FDA Accelerated Approval Of KRESLADI Gene Therapy [Yahoo! Finance]
Rocket Pharmaceuticals: Kresladi Approval Validates Platform, But Commercial Upside Remains Limited [Seeking Alpha]
Rocket Pharmaceuticals (RCKT) had its "buy" rating reaffirmed by Chardan Capital. They now have a $11.00 price target on the stock.